Posted by Michael Wonder on 23 Oct 2022
Could more medicines be recommended for routine commissioning rather than spending time in the Cancer Drugs Fund?
19 October 2022 - A new analysis commissioned by the ABPI suggests they could.
The Cancer Drugs Fund has successfully provided an early access mechanism for many cancer medicines. In 2016 it was brought under NICE’s remit and has since allowed more than 51 recommendations to be made whilst additional evidence is generated.
